Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
6 Famous Urban communities for Shopping on the planet - 2Authentic Urban areas: Rich Legacy and Lively Societies
- 3No more attempts to free whale stranded off Germany, officials say
- 4In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- 55 Breakout Stars in Ongoing television Series
- Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman?
- UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- Uncover the Manageable Fish Practices: Sea agreeable Feasting
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Antivirus Programming for Exhaustive Security
- Can humans have babies in space? It may be harder than expected
- Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
- 'Crammed into a cell with vermin at New Year'
